Transaction · 0000914190-26-000121
TECHBIO-TECHNE Corp
Hippel James
Hippel James, CFO, reported a transaction classified as return at BIO-TECHNE Corp involving 34982.000000 shares for an estimated $0.00. Reported holdings after the transaction were 2332.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
returnSEC transaction code DCFO
- Trade date
- Aug 15, 2026
- Filing date
- Aug 18, 2026
How reported position traded is calculated
Not calculated for derivative securities.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
TECH price since this filing
Daily closing prices, with the filing date and available return windowsTECH · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -0.6%1w ago +0.1%1d ago +0.2%
Returns since7d +0.2%30d +0.3%90d180d1y
Transaction facts
Stored Form 4 columns with their raw values
- Type
- return Code D
- Identifier
- 0000914190-26-000121 Performance Stock Options (Right to Buy)
- Transaction date
- Aug 15, 2026 Filed Aug 18, 2026, 09:13 PM · 3d delay
- Shares
- 34,982 sh $0.00 per share
- Estimated value
- $0 Computed from shares × price
- Holdings after
- 2,332 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Direct Ownership Large Holdings Reduction
Filing-only score
-10 points
Compact filing score computed from stored Form 4 facts. Version v1.
Mixed or weak signal
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - derivative_transaction-16 points
is_derivative = true
Derivative exercise rows are less discretionary than open-market purchases.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
Reported roles
CFO
Officer YesDirector No10% NoOther No
Footnotes & amended
- F1
Fully exercisable.
- F2
Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.
- F3
On 8/15/2026, the Board of Directors authorized discretionary vesting for 866 performance RSUs. The remainder of the performance RSUs were forfeited.
- F4
On 8/15/2026, the Board of Directors authorized discretionary vesting for 2,332 performance options. The remainder of the performance options were forfeited.
- F5
Options to purchase 11,481 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027, and options to purchase 11,480 shares vest on 8/15/2026.
- F6
Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F7
4,010 restricted stock units vest on 8/15/2026; and 4,011 restricted stock units vest on 8/15/2027.
- F8
Options to purchase 8,104 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 8,105 shares vest on 8/15/2028.
- F9
11,545 restricted stock units vest on 11/1/2026; and 11,544 restricted stock units vest on 11/1/2027.
- F10
Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F11
4,903 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 4,904 restricted stock units vest on 8/15/2028.
- F12
Options to purchase 12,544 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
Related transactions
Same SEC filing0 other transactions
Recent company activity
TECH0 recent txs